transcription factor (ZFP TF(TM)), designed to upregulate the vascular
endothelial growth factor-A (VEGF-A) gene.
* Official launch of Sigma-Aldrich CompoZr(TM) platform of zinc finger
nuclease (ZFN) reagents for gene-editing. In September, Sangamo's
partner, Sigma-Aldrich Corporation (Nasdaq: SIAL), the exclusive
distributor of ZFP products for research applications, launched sales
of CompoZr ZFN reagents. The CompoZr ZFN platform of reagents is
expected to provide researchers with the ability to target and
precisely manipulate the genome of living cells, resulting in cell
lines or whole organisms with defined gene deletions, insertions, or
corrections. Initially offered as a customized service for developing
ZFNs for specific gene targets, the CompoZr ZFN platform will
eventually include ZFN-based kits for targeted transgene insertion and
a catalog of off-the-shelf reagents for commonly studied gene targets,
gene families, and pathways. For more information on Sigma-Aldrich's
CompoZr zinc finger nuclease technology platform, visit
http://www.compozrzfn.com or contact a sales representative at
Sangamo will host a conference call today, October 29, 2008 at 5:00
p.m. ET, which will be open to the public. The call will also be webcast
live and can be accessed via a link on the Sangamo BioSciences website in
the Investor Relations section under "Events and Presentations"
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved